Sorted By:


Medicare Monday: Strengthening access to vaccines for seniors

PhRMA  |  Blog Post

Biopharmaceutical researchers are pursuing new techniques and strategies in vaccine development, such as the use of genomics, to address these and other challenges, creating new opportunities to protect against many more life-threatening diseases in the future.

The Science of Hope: Understanding biomarkers

PhRMA  |  Blog Post

  Read more about proactive policy solutions to modernize the FDA and deliver innovative treatments to patients here.

Stephen J. Ubl to Lead PhRMA as Next President and CEO

PhRMA  |  Press Release

Ubl has a long track record of working collaboratively with a broad array of health care stakeholders, including patient advocacy organizations, providers and public and private payers.

340B Spotlight: Health Care Costs Rising from Increase in 340B Hospital Acquisitions of Physician Practices

PhRMA  |  Blog Post

In fact, the study found the average reimbursement for Part B oncology drugs was 52 percent higher in 340B hospitals than in community cancer clinics, when compared on a per Medicare beneficiary basis.

Critics Proven Wrong Again on Medicine Spending

PhRMA  |  Fact Sheet

Over the past year, payers claimed life-changing treatments and cures for hepatitis C and high cholesterol would bankrupt the health care system and wreck financial havoc.

Why reauthorization of PDUFA matters

PhRMA  |  Blog Post

Get the facts on how PDUFA harnesses real-world evidence to provide patients with innovative, new medicines.

Making Chemo More Tolerable

From Hope To Cures  |  From Our Network

Oasmia’s approach is to coat the drugs with nanoparticles that make them water soluble, with the aim of lowering side effects and reducing the time an infusion takes.

Center for Medicare and Medicaid Innovation

PhRMA  |  From PhRMA

CMMI’s broad testing authority results in unchecked ability for the agency to make rapid, broad and unpredictable changes to payment policy.

Zika Virus: Current Outbreak and Ongoing Research Efforts

PhRMA  |  Fact Sheet

Symptoms of the disease are usually mild, including fever, joint pain, rashes, and viral conjunctivitis (red/itchy eyes), and appear within a week of being exposed.


PhRMA  |  From PhRMA

PhRMA frequently hosts and participates in online and in-person events that delve into the science, policy and regulatory issues critical to biopharmaceutical innovation and patient access to medicines.

Glenn J. Gormley, MD, PhD

PhRMA  |  Biography

He has remained committed to the fields of clinical pharmacology and endocrinology and published many papers of original research.

Support Patient Protections for Employees

Access Better Coverage  |  From Our Network

The overutilization of some cost controls undoubtedly lead to workers spending more time dealing with or worrying about the bureaucratic hurdles they must navigate to obtain proper care for themselves and their families.

PhRMA Statement on Trump Opioids Announcement

PhRMA  |  Press Release

And we recently announced the industry’s support for a 7-day script limit on opioids for acute pain as part of a comprehensive set of forward-leaning policy solutions that will be laid out in more detail over the coming weeks.

Medicare Monday: Kicking off 2017 with Medicare resources

PhRMA  |  Blog Post

Check out our Part D resources page.

Partnership for Prescription Assistance Celebrates Milestone Helping More Than 6 Million Uninsured Patients

PhRMA  |  Press Release

However, that frightening incident altered his view of the disease: “I realized that I was in a life-threatening situation, and I needed to do everything I could do, in my power, to understand what I was dealing with and what I was stricken with.”

Medicare Monday: Provider consolidation drives up costs for patients and government

PhRMA  |  Blog Post

A study conducted by Milliman for the Community Oncology Alliance, released earlier this month, found from 2004 to 2014 spending on chemotherapy infusions shifted from less expensive physician offices to more expensive hospital outpatient facilities, resulting in a rise in per-patient-per-year costs.

Medicare Monday: A guide to MedPAC’s Part B vote this week

PhRMA  |  Blog Post

Keep an eye on MedPAC activity later this week to see what happens with these draft recommendations.

Milliman - 2016 Medicare Part D National Average Value Drivers

PhRMA  |  Report

PhRMA requested examination of the impact on the national average bid amount (NABA) and national average member premium (NAMP) per member per month as a result of various factors.

Olivier Brandicourt

PhRMA  |  Biography

Prior to Bayer Healthcare, Brandicourt worked at Pfizer for 13 years, where he most recently served as a member of the Executive Leadership Team and as President and General Manager of the Emerging Markets and Established Products business units.

New Report: Past Drug Failures Help Create the War on Cancer’s Next Successes

PhRMA  |  Press Release

“These setbacks serve as a reminder that to make progress, we need a public policy framework that supports drug development in combination with promising science so that we can bring important innovations to patients.”

Prescription Medicines: Costs in Context

PhRMA  |  From PhRMA

View PhRMA’s policy solutions for delivering innovative treatments to patients.

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

Healthy Outlook: Nicole Sweeney of Boston Healthcare Associates contributed a guest post this week highlighting their new white paper, “The Value of Innovation in Oncology: Recognizing Emerging Benefits Over Time.”

New Report: Part B proposal is more aggressive than previous efforts

PhRMA  |  Blog Post

“CMMI’s approach to introducing changes to the Medicare and Medicaid programs using its unique regulatory authority rather than a legislative process represents a significant evolution in how HHS is executing its authority, which warrants close attention,” the paper explains, also reiterating the critical importance of measurement and evaluation in developing models.

NHE Data: Medicine spending grew just 1.3 percent in 2016

PhRMA  |  Blog Post

All major payers (Medicare, Medicaid and commercial health plans) experienced slower retail medicine spending growth in 2016.

PhRMA’s Rick Smith Testifies Before the Senate Aging Committee

PhRMA  |  Press Release

(May 22, 2013) – Richard Smith, Executive Vice President of Policy and Research at Pharmaceutical Research and Manufacturers of America (PhRMA), testified today in a hearing called “10 Years Later: A Look at the Medicare Prescription Drug Program,” hosted by the U.S.

You have reviewed the first 400 results out of 1100. Each page contains 25 results. You're on page 16.

prev 13 14 15 16 17 18 next